(Reuters) - - Impax Laboratories said it was subpoenaed by the Connecticut Attorney General regarding an investigating into possible price fixing of its generic heart drug, digoxin. Besides price ...
HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that its generics division, Global Pharmaceuticals, commenced shipment of authorized generic Zomig® ...
Sept 14 (Reuters) - Impax Laboratories Inc and Israel's Teva Pharmaceutical Industries Ltd settled a two-year patent dispute with Johnson & Johnson, allowing the generic drugmakers to start selling a ...
In March 2013, the US Food and Drug Administration (FDA) formally withdrew approval for Impax Laboratory's buproprion hydrochloride extended release 300 mg (Budeprion XL 300 mg), saying the drug had ...
Sandoz was hit with a patent infringement lawsuit on Nov. 12 in New Jersey District Court over its attempt to market generic versions of Crexont, a Parkinson's disease treatment. The action, brought ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results